FDA Approves GSK's Blenrep for Multiple Myeloma Treatment
TL;DR
The FDA approved GSK's blood cancer drug Blenrep for use in one combination regimen but rejected another, marking a complex decision in the drug's regulatory history.
- FDA delivers split decision on GSK’s blood cancer drug Blenrep, approving its use in some cases statnews.com
- US health agency reapproves GSK blood cancer drug after new trial Financial Times
- US FDA approve GSK's blood cancer treatment Reuters
- FDA brings GSK’s Blenrep back to the market in multiple myeloma Endpoints News
- Blenrep approved by US FDA for use in treatment of relapsed/refractory multiple myeloma Yahoo Finance
Want the full story? Read the original reporting
Read on statnews.com